RNAi targeting heparin cofactor II promotes hemostasis in hemophilia A

Wen-yi Lin,1,2 Ruiqi Zhu,1,2 Zhen Zhang,1,2 Xuan Lu,1 Huafang Wang,1 Wenjuan He,1 Yu Hu,1 and Liang Tang1

Hemophilia A is a hemorrhagic disease due to congenital deficiencies of coagulation factor VIII (FVIII). Studies show that hemophilia patients with anticoagulant deficiency present less severe hemorrhagic phenotypes. We aimed to find a new therapeutic option for hemophilia patients by RNA interference (RNAi) targeting heparin cofactor II (HCII), a critical anticoagulant protein inactivating the thrombin. The optimal small interfering RNA (siRNA) was conjugated to an asialoglycoprotein receptor ligand (N-acetylgalactosamine [GalNAc]-HCII), promoting targeted delivery to the liver. After administration, GalNAc-HCII demonstrated effective, dose-dependent, and persistent HCII inhibition. After 7 days, in normal mice, GalNAc-HCII reduced HCII levels to 25.04% ± 2.56%, 11.65% ± 2.41%, and 6.50% ± 1.73% with 2, 5, and 10 mg/kg GalNAc-HCII, respectively. The hemostatic ability of hemophilia mice in the GalNAc-HCII-treated group significantly improved, with low thrombus formation time in the carotid artery thrombosis models and short bleeding time in the tail-clipping assays. After repeated administration, the prolonged activated partial thromboplastin time (APTT) was reduced. A 30 mg/kg dose did not cause pathological thrombosis. Our study confirmed that GalNAc-HCII therapy is effective for treating hemophilia mice and can be considered a new option for treating hemophilia patients.

INTRODUCTION

Hemophilia A (HA) is a congenital hemorrhagic disorder caused by the absence of coagulation factor VIII (FVIII). In more than 90% of cases, the first symptoms develop in childhood, presenting hemorrhage primarily in the skin, joints, and deep tissues. Severe cases may develop hemophilic arthropathy leading to joint deformities or present intracerebral hemorrhage, causing permanent neurological sequelae and even death.1,4 In the past, for the management of hemophilia, intravenous supplementation of clotting factors is performed two or three times per week, demonstrating low patient compliance, high cost, and production of inhibitory antibodies after long-term treatment.5 Recently, gene therapy has been explored and proved to be a promising therapeutic option for hemophilia.5,6 For example, the recombinant FVIII (N8-GP) has a longer half-life, lower immunogenicity, and superior hemostatic efficacy.5 Also, recombinant adeno-associated virus (AAV) delivery of FVIII has shown very promising efficacy in several preclinical and clinical studies.6 As the routine prophylaxis and treatment, a recently developed drug emicizumab, mainly connecting FIX and X for exerting the FVIIIa cofactor function to rebuild the disordered coagulation system, is now widely approved for patients.5,9 Moreover, the inhibition of anticoagulants to correct hemorrhage tendency has exhibited superior effectiveness and specificity as expected, such as antithrombin III (ATIII; fitusiran), tissue factor pathway inhibitor (TFPI; concizumab), activated protein C (APC; KRK z1AT), and protein S (PS; PS small interfering RNA [siRNA]).10-13 These are attractive, innovative approaches with excellent prospects for clinical applications but having some limitations to their efficacy and safety. For example, to maintain the level of supplementary factors in plasma for successfully preventing hemorrhage, the standard dosing regimen of recombinant FVIII needs to be further determined because of individual differences of FVIII activity.14,15 Although AAV gene therapy is a great success, some significant safety concerns are associated with it, such as the genotoxicity of viral integration and the immune responses against the virus in humans.16,17 Despite a proven clinical application, the efficacy of emicizumab is not indicated in hemophilia B.18 A patient who participated in one of the clinical trials of fitusiran suffered cerebral sinus venous thrombosis after FVIII treatment, resulting in death. Therefore, further risk assessment is necessary to ensure the safety of fitusiran usage.19 The potency of KRK z1AT has been proven in animals, but its side effects on other systems need deeper exploration and evaluation because of the strong anti-inflammatory and cytoprotective roles of APC.20 Similarly, it remains to be observed how PS siRNA influences the complement system for which PS participates in humans’ complement regulation.21 In order to obtain stable therapeutic effects, further research and development are needed for concizumab because the plasma drug concentration varies significantly among patients taking the same dosage.22 It is thus essential to find more effective and safer approaches to meet the extensive need for HA treatment.

Received 22 October 2020; accepted 31 March 2021; https://doi.org/10.1016/j.omtn.2021.03.022.
2These authors contributed equally

Correspondence: Liang Tang, Institute of Hematology, Union Hospital Affiliated Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Dadao, Wuhan 430022, China. E-mail: lancet.tang@qq.com

Correspondence: Yu Hu, Institute of Hematology, Union Hospital Affiliated Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Dadao, Wuhan 430022, China. E-mail: dr_huyu126.com
Heparin cofactor II (HCII), containing 480 amino acid residues, is a serine protease inhibitor encoded by the SERPIND1 gene. It is secreted by the liver and circulates in the plasma at 1.2 ± 0.4 μmol/L. Being one of the homologous proteins of ATIII, HCII plays a vital role in the anticoagulant system with its typical thrombin inhibition mechanism. Unlike ATIII with several target proteases (thrombin, FXa, and FIXa), HCII specifically inhibits thrombin and does not affect other coagulants (Figure 1). This is due to different residues at the active site (Arg for ATIII, Leu for HCII), leading to inconsistent binding sites with thrombin. Under normal physiological conditions, a third of thrombin is inactivated by HCII at a slow basal rate. Its efficiency to inactivate thrombin is about 1/10 of ATIII. However, the activity of HCII can be significantly enhanced by the catalysis of glycosaminoglycans (heparin, heparan sulfate, dermatan sulfate [DS]), etc., which promotes the acidic N terminus of HCII that binds tightly to the anion-binding exosite I of thrombin for rapidly forming the thrombin-HCII complex. As a specific catalyst, DS can increase the activity of HCII by more than 1000-fold, much higher than heparin and heparin sulfate. This is primarily due to the different binding sites with HCII. DS is synthesized by vascular smooth muscle cells and fibroblasts and generally exists on the blood vessel walls. This indicates that HCII mainly plays a role in connective tissues, while ATIII mostly in plasma. When the vessel wall is damaged, HCII enters it and comes in contact with DS to exert its anticoagulant effect.

The physiological function of HCII is relatively single. Studies have shown that lack of HCII does not interfere with hematopoiesis and pregnancy and does not cause clinically severe complications or death. Besides, many case reports found that individuals with HCII deficiency had a medical history of thrombotic diseases. Lopaciuk et al. have reported a significantly higher prevalence of HCII deficiency in thrombotic patients than in controls (5.7% versus 0.9%). Furthermore, a previous study indicated that compared with wild-type (WT) control mice, HCII depletion mice had significantly shorter thrombus formation time under vascular damage (34 ± 4 versus 60 ± 12 min). Therefore, we speculated that the reduction of HCII might promote hemostasis in bleeding disorders, such as hemophilia. This study aimed to explore the effect of RNA interference (RNAi) therapy targeting HCII on the coagulation pathway and confirm a novel way for hemostasis in HA patients.

**RESULTS**

**In vitro thrombin generation tests (TGTs)**

In hemophilia, it is confirmed that the ability of thrombin generation in plasma is associated with the clinical severity of the bleeding phenotype. To evaluate the effect of HCII reduction on the hemostatic capacity in hemophilia plasma, we measured the thrombin levels in FVIII-deficient plasma depleted of HCII to 9.7%, including peak thrombin and endogenous thrombin potential (ETP). Because the ability of HCII to inactivate thrombin was determined by DS content with different tissue distributions, we had set up various levels of DS in TGT to assess the potency of decreased HCII for thrombin generation accurately. In the absence of DS, results showed that there was no significant difference in thrombin generation between HCII-reduced (9.7%) and HCII normal (100%) groups (peak thrombin, p = 0.435; ETP, p = 0.987) (Figure 2A; Table 1). After adding a large amount of DS (250 μg/mL), thrombin was entirely inhibited in healthy control and HCII normal groups. However, the reduction of HCII promoted the generation of thrombin (Figure 2B; Table 1). Furthermore, it demonstrated an additive thrombin generation response to recombinant human FVIII (rhFVIII) in the background of reduced and not reduced HCII. However, neither the peak thrombin nor ETP in the HCII-diminished group with rhFVIII surpassed healthy control (p = 0.143 and p = 0.769). Thus, the risk for thrombin overproduction, namely, the potential risk of thrombosis, may be low in the HCII-reduced plasma even with the replacement factor (rhFVIII). Also, we demonstrated that the depletion of HCII did not affect other anticoagulants’ activities, such as antithrombin (AT), protein C (PC), and PS, indicating that the alteration of thrombin generation was due to only the reduction in HCII activity (Figure S1). Our results were per the hypothesis that the decreased expression of HCII protein could effectively and safely rebalance the coagulation and anti-coagulation pathways to improve the hemostatic ability in hemophilia plasma.

**Pharmacokinetics and pharmacodynamics in WT mice**

The RNAi therapeutic technology was applied to the present study to inhibit the expression of HCII in vivo. An optimal siRNA targeting the HCII gene was screened out via cellular assays (siRNA-HCII). HCII mRNA levels, consistent with the protein alterations, were significantly reduced in the siRNA-HCII-treated group, about 6.65% ± 1.61% and 6.17% ± 4.50% relative to the siRNA-control-treated group in mouse
Hepa 1–6) or human (HepG2) cells (Figures 3A and 3B). This siRNA was then conjugated to the GalNAc ligand and was chemically modified for specific delivery to hepatocytes and stable inhibition of HCII in vivo (Figure 3C).

After a single subcutaneous injection, GalNAc-HCII rapidly diffused into the plasma with maximum concentrations that appeared after 30 min, about 0.30, 0.39, and 0.95 µg/mL for dosages of 2, 5, and 10 mg/kg, respectively. Drug levels significantly decreased at 4 h after dosing (Figure 4A). Simultaneously, the levels of GalNAc-HCII in the liver increased promptly, showing the peak concentrations with 6.2, 29.0, and 59.3 µg/g for administrations of 2, 5, and 10 mg/kg, respectively. The drug remained in the liver for a long time, up to 2 weeks (Figure 4B). The concentration of GalNAc-HCII in the liver and plasma was predominantly dependent on the administered dosage. Furthermore, to verify the liver specificity of GalNAc-HCII, we observed the drug levels in other organs, which were relatively low or even below the limit of quantitation (Figures S2A–S2D). In addition, we analyzed frozen sections of the liver after the administration of GalNAc-HCII at 1 mg/kg labeled with cyanine dye 3 (Cy3). Results showed that the drug specifically targeted the liver with utmost fluorescence intensity emerging at 4 h after dosing, and no drug accumulation was observed in other organs (Figure 4C; Figure S2E). Alterations in the fluorescence intensity were consistent with the drug pharmacokinetics curve mentioned above.

Furthermore, we explored the inhibition efficacy of GalNAc-HCII in WT mice. After a single subcutaneous administration, dose-dependent inhibition of HCII protein levels was observed in the plasma. The greatest inhibitory potency appeared on day 7, with relative HCII protein level reduced to 25.04% ± 2.56%, 11.65% ± 2.41%, and 6.50% ± 1.73% at doses of 2, 5, and 10 mg/kg, respectively. HCII suppression was long-lasting with the maintenance of protein levels less than 50% for 7 and 21 days at dosages of 2 and 5 mg/kg. Moreover, a high dose of 10 mg/kg resulted in maintenance of HCII levels less than 20% for 14 days (Figure 5A). As expected, the inhibition of HCII antigen in plasma was correlated with reductions of plasma HCII activity, liver HCII mRNA, and HCII protein, per the mechanism of RNAi action (Figures S3A–S3C). When dosed repeatedly, GalNAc-HCII induced dose-dependent, persistent suppression, with HCII protein decreased to stable levels (≈20%) after 2 weeks of administration (Figure 5B).

The hemostatic capacity of HA mice
To explore the hemostatic effects of HCII reduction in HA mice, we generated carotid artery thrombosis models to evaluate the capacity of thrombus formation. Stable thrombus formation was observed at the carotid artery after induction by ferric chloride solution (FeCl₃) in GalNAc-HCII-treated HA mice (15/15), while no stable clot was observed in the phosphate-buffered saline (PBS)-treated HA group (0/4). The time of thrombus formation was closely correlated to the doses, with approximately 19.6 ± 3.05, 11.6 ± 1.82, and 8.2 ± 1.64 min for 2, 5, and 10 mg/kg, respectively (Figure 6A; Figure S4). Moreover, there was no significant difference in thrombus formation time between WT and HA mice administered GalNAc-HCII at a dosage of 10 mg/kg (p = 0.996). Because factor replacement is an important therapy in hemophilia, we needed to compare the hemostatic potency of GalNAc-HCII and rhFVIII treatments for HA mice. Results showed better hemostatic capacity when dosed with 10 mg/kg in GalNAc-HCII-treated mice compared with rhFVIII supplementary group (p = 0.014), while no difference was observed between HA mice administered a dose of 5 mg/kg and rhFVIII (p = 0.927).

We then conducted a tail-clipping assay to evaluate further the effect of HCII depletion on the hemostatic ability in HA mice. HA mice treated with GalNAc-HCII showed significantly shortened bleeding time of the tail artery (15/15), while most HA mice treated with PBS could not stop bleeding within 30 min (3/4). A dose-dependent effect was observed for bleeding time, with approximately 13.9 ± 1.88, 8.0 ± 1.84, and 7.3 ± 0.97 in the GalNAc-HCII-dosed group at 2, 5, and 10 mg/kg, respectively (Figure 6B). When administered 5 or 10 mg/kg, the hemostatic potency of the GalNAc-HCII-dosed group was similar and showed no difference to that of the WT group (p = 0.129 and p = 0.298). As an additional control, four animals were administered 100 IU/kg rhFVIII before tail clipping. Results showed better hemostatic effect when dosed with 5 or 10 mg/kg in GalNAc-HCII-treated mice compared with the animals supplemented with...
rhFVIII (p = 0.013 and p = 0.004), whereas no difference was observed between groups administered GalNAc-HCII at 2 mg/kg and rhFVIII (p = 0.923).

Activated partial thromboplastin time (APTT) is an important evaluation index of the hemostatic ability in hemophilia. Prolonged APTT was evident in HA mice with PBS due to abnormal coagulation mechanisms. At 7 days after single dosing, mice treated with GalNAc-HCII showed a reduced APTT, with 64.8 ± 9.7% at 2 mg/kg, 35.7 ± 10.0% at 5 mg/kg, and 22.8 ± 11.0% at 10 mg/kg, respectively. Moreover, according to APTT values in plasma with various FVIII levels, the correction effects of APTT in HA mice with GalNAc-HCII corresponded to approximately 6.6% ± 1.6%, 19.7% ± 1.6%, and 22.8% ± 3.3% normal levels of FVIII protein in vivo (Figure S5). Although the correction capacity of APTT was not better than for the rhFVIII supplementary group, the maintenance of APTT was more durable in GalNAc-HCII-dosed mice, with 10 and 14 days for 5 and 10 mg/kg, respectively (Figure 6C). After repeated administration, the APTT was further reduced in the GalNAc-HCII-treated group but did not reach normal levels of WT mice (35.7 ± 5.3 s), even when the HCII inhibition was over 80% (Figure 6D; Figure S6).

### Acute toxicity studies
To assess the short-term accumulation effects and acute toxicity of GalNAc-HCII in vivo, we gave repeated injections of 30 mg/kg. Both WT and HA mice well tolerated the drug after 2 weeks of administration, with no abnormal phenotypes and no significant alterations in some hematological indexes, including complete blood count (CBC), renal functions, and myocardial enzymes. Nevertheless, the slight elevation of liver function indexes was observed in all mice treated with GalNAc-HCII or GalNAc-control, involving alanine transaminase (ALT), aspartate aminotransferase (AST), and total bilirubin (T-BIL) (Figure 7A; Figures S7A–S7C). There was no difference in liver functions between GalNAc-HCII- and GalNAc-control-dosed groups. Results of histopathological sections indicated mild liver injury in treated groups, characterized by punctate hepatocyte necrosis with leukocyte infiltration and hepatic degeneration in the focal perivascular (Figure 7B). Moreover, no difference of serum HCII levels was observed between HA mice dosed with GalNAc-control and PBS (p = 0.919; Figure S7D). It suggested that the liver damage was related to generalized toxicity from repeated GalNAc-RNAi molecules, but not to the knockdown of HCII. In addition, no death occurred in all groups at this dosage and frequency of administration.

### Potential risk for thrombosis
Because thrombotic events have been reported in hemophilia patients with fitusiran after FVIII replacement treatment, we need to evaluate the potential risk for thrombosis in HA mice receiving GalNAc-HCII therapy, especially those given hemostatic agents at the same time. After repeated dosing of 30 mg/kg, no edema or paleness was observed in the upper and lower limbs. Results of organs anatomy showed no abnormalities in the size, shape, color, and weight. Then plasma was collected. As expected, results of TGT indicated improved thrombin generation
in GalNAc-HCII-dosed mice compared with untreated HA mice. After supplemented FVIII, a more obvious elevation of thrombin levels was observed in HA mice with or without GalNAc-HCII, but neither different from the normal level of WT mice (peak thrombin, p = 0.113 and p = 0.926; ETP, p = 0.792 and p = 1.00) (Figure 7C; Table 2). In accordance with the results above, APTT exhibited a decrease in GalNAc-HCII-injected mice with not reaching the normal value of WT mice. Although significantly corrected with rhFVIII, APTT still does not surpass the normal range of WT mice (Figure 7D).

**DISCUSSION**

It has been reported that HA patients with anticoagulant deficiency present less severe hemorrhagic phenotypes. This study suggested that on reducing HCII, an important anticoagulant protein, specifically inactivating thrombin, thrombin generation could be upregulated, and the hemostatic ability of HA mice could be significantly improved. Therefore, targeting HCII may be a potential treatment for HA.

We know that the inactivation rate of thrombin by HCII is regulated explicitly by DS. For the absence of DS in commercial FVIII-deficient plasma, the ability of HCII to inactivate thrombin is relatively low, whether it is reduced or not, resulting in higher thrombin generation than that of hemophilia patient plasma in other research works. After adding DS, we found that thrombin levels in the HCII-reduced group with DS at low concentrations were much lower than that of high concentrations for the dose-dependent regulation of DS on HCII. The higher the concentration of DS, the more the thrombin is inactivated by HCII, which means that thrombin will be retained more when HCII is reduced. In addition, even in the presence of DS with high concentrations, the thrombin generation curve was not corrected to the normal level. This is because HCII just inactivates a part of thrombin in vivo even with the maximum activity, and the HCII reduction did not affect the inactivation of thrombin by other anticoagulants. These data also suggested that HCII reduction was relatively safe for avoiding excessive thrombin production to over-activate coagulation. Furthermore, HA mice supplemented with rhFVIII did not obtain the hemostatic capacity equivalent to that of WT mice, whereas suppression of HCII did. Possible reasons are as follows: the rhFVIII mainly affects the production of thrombin in plasma, while HCII inhibition primarily affects the injured vessels for DS’s existence. In our study, mice models primarily involving vascular damage resulting in rhFVIII could not prove themselves adequately. This may be one reason why APTT in HA mice with HCII suppression was not corrected to normal, reflecting the coagulation in plasma.

Heterozygous HCII deficiency has been reported to be associated with thromboembolic events, but some epidemiological studies suggested that heterozygous HCII deficiency is as common in healthy people as in patients with deep vein thrombosis (DVT). The first subject with homozygous HCII deficiency had been reported for recurrent thrombosis, which was confirmed to be accompanied by ATIII deficiency. A screening study of thromboembolic events in adolescents revealed two patients with HCII Rimini mutation, and they were proved to be complicated with FV Leiden mutation and type I PC deficiency. Besides, it was shown that mice with homozygous

![Figure 3. The reduction effects of siRNA-HCII in cellular assays and the synthesis of GalNAc-modified siRNA-HCII](image)
HCII deficiency presented significantly shorter time of thrombus formation in the carotid artery after endothelial injury. However, no evidence of spontaneous thrombosis was found in mice without induction. Accordingly, HCII deficiency may play a limited role as a risk factor for thrombosis in vivo. Patients with HCII deficiency are likely to have a thrombotic tendency when other thrombogenic factors exist simultaneously, such as thrombophilia-related gene defects or obvious risk factors of thrombosis. One possible reason has been mentioned above that the activity of HCII in plasma is relatively low, and only a small part of thrombin is inactivated specifically. In addition, this study demonstrated that HCII inhibition mainly affected the hemostasis of damaged vessels with slightly improved thrombin levels and marginally shortened APTT. Even with the addition of rhFVIII, the thrombin generation and APTT in HCII-reduced groups still did not surpass the normal levels in vitro and in vivo. Moreover, pathological thrombosis was not found in the organs of mice after frequent injection of GalNAc-HCII. Therefore, our method is safer for significantly reducing the potential risks of thrombosis than other anticoagulant inhibition therapies.

Our research also has some shortcomings. First, acute hepatotoxicity was found in the GalNAc-HCII-treated group with large doses, which raised some concerns about the safety of this approach in patients with chronic liver diseases, such as fibrosis and cirrhosis. It is essential for us to develop more toxicity-reducing studies in the future to improve the feasibility of this therapy for patients with liver diseases. Second, our protocols are limited to HA. In theory, for HA and hemophilia B, this treatment’s effect should be the same because HCII specifically acts on thrombin with no effect on other coagulation factors. However, due to the lack of FIX-deficient mice, this drug’s effects on hemophilia B and even other hemophilia types remain to be elucidated. Finally, some clinical studies have suggested that the concentration of HCII in plasma is negatively correlated to atherosclerosis and restenosis after angioplasty, which is due to the promotion of HCII deficiency to the neointimal formation and vascular remodeling. In our study, the period of explorations on pharmacodynamics and toxicity for GalNAc-HCII is relatively short. In addition, there are no hemophilia mice with atherosclerosis currently. So we fail to find apparent alterations of HCII inhibition on vascular intima, which may require further research.

This study aimed to elucidate a novel RNAi therapy for HA targeting HCII. This method has no mention in any of the previous studies. Our results suggest that it is an effective treatment for HA mice.
Although there are still some issues to be solved, this method represents a new idea for HA treatment and may provide a better choice for patients in the future.

MATERIALS AND METHODS

We have received informed consent from all subjects. This study was reviewed and approved by the Medical Ethical Committee and the Animal Ethics Committee of Union Hospital, Huazhong University of Science and Technology.

Preparation of plasma samples

Healthy control plasma was obtained from the mixture plasma of 15 healthy volunteers. The FVIII-deficient plasma (Hyphen Biomed, France) was used to simulate HA plasma from patients. The depletion of HCII in vitro was performed by adding HCII neutralizing antibody (Affinity Biologics, ON, Canada) to the FVIII-deficient plasma in the ratio 1:9, which leads to the activity of HCII reduced to 9.7%, detected by the chromogenic substrate method. Activities of ATIII, PC, and PS in human plasma samples were detected on an automatic coagulator (Sysmex, Japan) by corresponding kits according to the manufacturer’s instructions (Siemens Healthcare Diagnostics, Germany). Further control plasma was generated by adding rhFVIII (obtained from Union Hospital) to the FVIII-deficient plasma at 1 IU/mL to recover the thrombin generation to the normal level of healthy control.

The plasma of mice was obtained from the inferior vena cava by adding 3.8% sodium citrate (1:9). All plasma samples were centrifuged at 2,000 × g for 20 min to obtain platelet-poor plasma (PPP) and then stored at −80°C until use. The plasma of HA mice was diluted with WT mice plasma in different ratios to generate HA plasma with various levels of FVIII. APTT and FVIII activity of mixture plasma was measured on the coagulation analyzer (Diagnostica Stago, France).

TGT

TGT was conducted in human and animal plasma samples through an automatic thrombin generation detector (Thrombinoscope, the Netherlands) according to the manufacturer’s protocols. Before measuring thrombin generation, DS (Affandi-e, China) was added to human plasma with various concentrations (0, 25, 250 µg/mL). The coagulation pathway was activated by adding tissue factors (1 pm), phospholipids (4 mM), and FluCa kit (containing CaCl2) to the plasma. Then, thrombin was generated to cleavage the fluorescent substrates to release signals for detection.

Cell culture and siRNA transfection

Hepatocyte cell lines (mouse: Hepa 1–6; human: Hepg2), purchased from the cell bank of the Chinese Academy of Sciences, were maintained in DMEM (Gibco, Carlsbad, CA, USA) supplemented with 10% FBS (Gibco, Carlsbad, CA, USA). Cell lines were seeded in a six-well plate at a density of 10^5 cells/well. After 24 h, cells were transfected with an optimal siRNA targeting HCII gene (siRNA-HCII, 5’-UGGUGGAGAGAUGGCAAAAAA-3’, suitable for mouse and human) or a negative control siRNA (siRNA-control, 5’-UUCUCC GAACGUGUCACGU-3’, suitable for mouse and human) (100 pmol) by using Lipofectamine 3000 (Invitrogen, USA). 48 h later, total RNA was extracted using the TRIzol reagent (Takara, Japan). After reverse transcription, quantitative real-time PCR was performed to detect the relative abundance of HCII mRNA normalized to the housekeeping gene GAPDH using a ChamQ SYBR qPCR Master Mix (Vazyme, China).

Besides, western blotting (WB) was conducted to assess protein levels of HCII relative to the internal control (GAPDH). Total cellular lysates (30 µg/lane) were separated on 10% SDS-PAGE gels. The proteins were transferred onto polyvinylidene fluoride (PVDF) membranes. Afterward, the membranes were blocked and incubated overnight with the rabbit anti-mouse or human polyclonal antibodies against HCII (1:1,000) (Abclonal, BSN, USA) or GAPDH (1:1,000) (Antigen, China), followed by incubation with goat anti-rabbit immunoglobulin G (IgG) antibody (1:3,000) for 1 h. The enhanced chemiluminescence (ECL) reagent was used to visualize the target bands in an imaging analyzer (Bio-Rad, CA, USA), and the gray value of each band was quantified by an ImageJ software.

Synthesis of GalNAc-siRNAs

GalNAc-HCII and GalNAc-control were synthesized with the help of the TranSheepBio company (Shanghai, China). In brief, optimal siRNA-HCII and siRNA-control were chemically modified and conjugated to a asialoglycoprotein receptor ligand derived from N-acetylgalactosamine (GalNAc) to promote targeted delivery to the liver in vivo.
Physiology in mice

Male mice (C57BL/6, 6–8 weeks old) (GemPharmatech, China) were subcutaneously administered GalNAc-HCII at 2, 5, or 10 mg/kg (10 mL/kg body weight). At 0.5, 1, 2, 4, 12, 24, 48, 96, 168, 240, and 336 h of dosage, two mice were sacrificed at each dose level. Plasma and tissue samples, including liver, heart, spleen, lung, and kidney, were collected to assess for drug levels. Saline perfusion was used for mice before tissue acquisition and after blood collection. GalNAc-HCII levels in plasma and tissues were detected via stem-loop quantitative real-time PCR assays (Vazyme, China). The lower limit of detection range, determined in PBS-treated mice, was 0.001 μg/mL in plasma and 0.116, 0.137, 0.156, 0.235, and 0.254 μg/g in liver, heart, spleen, lung, and kidney. All detection values are normalized by subtracting the background values in PBS-treated mice, and those lower than the minimum quantitation were considered 0 μg/mL or 0 μg/g.

Another group of mice was dosed GalNAc-HCII labeled with Cy3 dye (TranSheepBio, China), excited by 550 nm and visualized at 570 nm, at each time point of administration, frozen sections (TranSheepBio, China), excited by 550 nm and visualized at 570 nm, at another group of mice was dosed GalNAc-HCII labeled with Cy3 dye and DAPI was observed to demonstrate the targeting specificity.

Pharmacokinetics in mice

Male mice (C57BL/6, 6–8 weeks old) (GemPharmatech, China) were subcutaneously administered GalNAc-HCII at 2, 5, or 10 mg/kg (10 mL/kg body weight). At 0.5, 1, 2, 4, 12, 24, 48, 96, 168, 240, and 336 h of dosage, two mice were sacrificed at each dose level. Plasma and tissue samples, including liver, heart, spleen, lung, and kidney, were collected to assess for drug levels. Saline perfusion was used for mice before tissue acquisition and after blood collection. GalNAc-HCII levels in plasma and tissues were detected via stem-loop quantitative real-time PCR assays (Vazyme, China). The lower limit of detection range, determined in PBS-treated mice, was 0.001 μg/mL in plasma and 0.116, 0.137, 0.156, 0.235, and 0.254 μg/g in liver, heart, spleen, lung, and kidney. All detection values are normalized by subtracting the background values in PBS-treated mice, and those lower than the minimum quantitation were considered 0 μg/mL or 0 μg/g.

Another group of mice was dosed GalNAc-HCII labeled with Cy3 dye (TranSheepBio, China), excited by 550 nm and visualized at 570 nm, at 1 mg/kg. At the different time point of administration, frozen sections of tissue samples were collected and stained with DAPI dye, excited by 358 nm, and visualized at 461 nm. The fluorescence intensity of Cy3 and DAPI was observed to demonstrate the targeting specificity of GalNAc-HCII by a fluorescence microscope (Olympus, Japan).

Pharmacodynamics in WT mice

Male mice (C57BL/6, 6–8 weeks old) were subcutaneously administered PBS or GalNAc-HCII at 2, 5, or 10 mg/kg (10 mL/kg body weight). At 3, 7, 10, 14, 17, and 21 days of dosage, plasma samples from retro-orbital were collected to detect HCII protein levels by an ELISA according to the manufacturer’s protocols (ELISA, Biorbyt, UK). Relative HCII levels at each time point are determined by normalizing to serum HCII concentration detected in PBS-treated mice. A separate cohort of mice was sacrificed at 3 days after dosing. HCII protein levels and activities were measured in plasma, as mentioned previously. Liver tissues were obtained, and the mRNA level of HCII was tested by quantitative real-time PCR. Another batch of mice was replently treated with GalNAc-HCII at 2, 5, or 10 mg/kg weekly for a total of 3 weeks. At 3, 7, 14, 21, and 28 days of dosage, relative HCII protein levels in plasma were detected using the method mentioned above.
the bleeding time recorded at no more than 30 min.\textsuperscript{11,13} Besides, at 7, 10, 14, 17 and 21 days after dosing, plasma from the retro-orbital in another batch of mice was collected to detect APTT.

A separate cohort of mice received three weekly injections of 2 or 5 mg/kg GalNAc-HCII or PBS for 2 weeks. On day 21 (7 days after the last dose), plasma was collected to measure APTT and HCII antigen levels by the method described above.\textsuperscript{52}

**Acute toxicity studies and potential risk for thrombosis**

WT (male, 6–8 weeks old) and HA mice (male, 6–8 weeks old) were administered GalNAc-HCII or GalNAc-control every 2 days at 0 and 30 mg/kg for six times. On the day of the last dosing, HA mice received 100 IU/kg rhFVIII once a day until the termination of the observation (3 days after the last dose). The clinical manifestations, such as weight, diet, activity, limbs, and survival, were observed in administration duration. Plasma was collected to detect thrombin generation, APTT, and biochemistry indexes, including liver functions (AST, ALT, T-BIL, direct bilirubin [D-BIL], albumin [ALB]), renal function (blood urea nitrogen [BUN], creatinine [CR], uric acid [UA]), and myocardial enzyme (creatinine kinase [CK], L-type lactate dehydrogenase [LDH-L]). Anatomy of organs, including heart, liver, spleen, lung, and kidney, was performed to evaluate the size, shape, color, and weight. Furthermore, histopathological sections of tissue samples were obtained to evaluate the microscopic appearance of cells by using a microscope (Olympus, Japan).\textsuperscript{52,57}

**Statistical analysis**

Data were expressed as group mean ± SD (standard deviation), and comparisons between the groups were analyzed using one-way ANOVA test with GraphPad Prism 8.0 software. The significance level was set at $p < 0.05$.

| Groups               | Lag time (min) | Time to peak (min) | Time to tail (min) | Peak thrombin (nM) | ETP (nM min) |
|----------------------|----------------|--------------------|--------------------|--------------------|--------------|
| WT-PBS               | 2.7 ± 0.5      | 5.8 ± 0.4          | 19.8 ± 1.8         | 195.8 ± 16.7       | 1125.0 ± 95.0|
| HA-PBS               | 10.2 ± 1.1     | 12.6 ± 0.5         | 30.3 ± 1.7         | 7.9 ± 2.5          | 72.3 ± 15.2  |
| HA-30 mg/kg          | 7.3 ± 0.5      | 11.2 ± 0.3         | 26.7 ± 0.8         | 27.9 ± 4.1         | 360.0 ± 38.9 |
| HA-rhFVIII           | 2.2 ± 0.2      | 5.5 ± 0.4          | 19.0 ± 1.3         | 192.2 ± 14.2       | 1124.0 ± 112.8|
| HA-30 mg/kg-rhFVIII  | 2.0 ± 0.2      | 4.9 ± 0.4          | 21.5 ± 0.6         | 218.9 ± 15.7       | 1089.0 ± 46.1|

Values are group mean ± SD.
SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.omtn.2021.03.022.

ACKNOWLEDGMENTS
The authors would like to thank the researchers and study participants for their contributions. This work was supported by the Program for HUST Academic Frontier Youth Team (no. 2018QYTD14).

AUTHOR CONTRIBUTIONS
W.L., R.Z., and Z.Z.: design of the study, collection and analysis of data, preparation of figures and tables, and drafting of the manuscript; X.L., H.W., and W.H.: preparation and revision of figures and tables; I.T. and Y.H.: supervision of the study. All authors reviewed the manuscript.

DECLARATION OF INTERESTS
The authors declare no competing interests.

REFERENCES
1. Peyvandi, F., Garagiola, I., and Young, G. (2016). The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet 388, 187–197.
2. Castaman, G., and Matino, D. (2019). Hemophilia A and B: molecular and clinical similarities and differences. Haematologica 104, 1702–1709.
3. Schep, S.J., Schutgens, R.E.G., Fischer, K., and Boes, M.L. (2018). Review of immune tolerance induction in hemophilia A. Blood Rev. 32, 326–338.
4. Weyand, A.C., and Pipe, S.W. (2019). New therapies for hemophilia. Blood 133, 389–398.
5. Swystun, L.L., and Liticirac, D. (2016). Gene Therapy for Coagulation Disorders. Circ. Res. 118, 1443–1452.
6. Tiede, A. (2015). Half-life extended factor VIII of the treatment of hemophilia A. J. Thromb. Haemost. 13 (Suppl 1), S176–S179.
7. Pasi, K.J., Rangarajan, S., Mitchell, N., Lester, W., Syngiling, E., Madan, B., Laffan, M., Russell, C.B., Li, M., Pierce, G.F., and Wong, W.Y. (2020). Multiview Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A. N. Engl. J. Med. 382, 29–40.
8. Yada, K., and Nogami, K. (2020). Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Biphasic Antibody, Emicizumab. Arterioscler. Thromb. Vasc. Biol. 40, 1148–1154.
9. Blair, H.A. (2019). Emicizumab: A Review in Haemophilia A. Drugs 79, 1697–1707.
10. Van Deeren, V.M., and Tollefsen, D.M. (1991). The N-terminal acidic domain of human heparin cofactor II mediates the inhibition of alpha-thrombin in the presence of glycosaminoglycans. J. Biol. Chem. 266, 20223–20231.
11. Pasi, K.J., Rangarajan, S., Georgiev, P., Mant, T., Creagh, M.D., Lissitchkov, T., Bevan, M., Russell, C.B., Li, M., Pierce, G.F., and Wong, W.Y. (2020). Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A. N. Engl. J. Med. 382, 29–40.
12. Blinder, M.A., Adams, T.E., Ivanciu, L., Camire, R.M., Baglin, T.P., and Huntington, J.A. (2017). Targeting activated protein C to treat hemophilia. Curr. Opin. Hematol. 24, 446–452.
13. Kitazawa, T., Esaki, K., Tachibana, T., Ishii, S., Soeda, T., Muto, A., Kawabe, Y., Igawa, T., Tsunoda, H., Nogami, K., et al. (2017). Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IXa/IXa and Xa/Xa, emicizumab, depends on its ability to bridge the thrombins. Thromb. Haemost. 117, 1348–1357.

14. National Hemophilia Foundation (2017). Alnylam Reports Patient Death in Fisatran Clinical Study. https://www.hemophilia.org/news/alnylam-reports-patient-death-in-fisatran-clinical-study.
15. Chowdary, P., Eichler, H., Jiménez-Yuste, V., Kavaki, K., Matsushita, T., et al. (2019). Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood 134, 1973–1982.
16. Polderdijk, S.G.I., Baglin, T.P., and Huntington, J.A. (2017). Targeting activated protein C to treat hemophilia. Curr. Opin. Hematol. 24, 446–452.
17. Polderdijk, S.G.I., Baglin, T.P., and Huntington, J.A. (2017). Targeting activated protein C to treat hemophilia. Curr. Opin. Hematol. 24, 446–452.
18. Dargaud, Y., Béguin, S., Lienhart, A., Al Dieri, R., Trzeciak, C., Bordet, J.C., Hemker, H.C., and Negrier, C. (2005). Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb. Haemost. 93, 475–480.

19. Lopaciuk, S., Bykowska, K., and Kopeč, M. (1996). Prevalence of heparin cofactor II deficiency associated with recurrent thrombosis. Lancet 348, 1303–1307.
20. Trzeciak, C., Bordet, J.C., Hemker, H.C., and NEGRIER, C. (2005). Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb. Haemost. 93, 475–480.
38. Huang, J.N., and Koerper, M.A. (2008). Factor V deficiency: a concise review. Haemophilia 14, 1164–1169.

39. Sprefico, M., and Peyvandi, F. (2008). Combined FV and FVIII deficiency. Haemophilia 14, 1201–1208.

40. Samuelson Bannow, B., Recht, M., Négrier, C., Hermans, C., Berntorp, E., Eichler, H., Mancuso, M.E., Klama, R., O'Hara, J., Santagostino, E., et al. (2019). Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis. Blood Rev. 35, 43–50.

41. Favaloro, E.J., Kershaw, G., Mohammed, S., and Lippi, G. (2019). How to Optimize Activated Partial Thromboplastin Time (APTT) Testing: Solutions to Establishing and Verifying Normal Reference Intervals and Assessing APTT Reagents for Sensitivity to Heparin, Lupus Anticoagulant, and Clotting Factors. Semin. Thromb. Hemost. 45, 22–35.

42. Tollefsen, D.M. (2002). Heparin cofactor II deficiency. Arch. Pathol. Lab. Med. 126, 1394–1400.

43. Villa, P., Aznar, J., Vaya, A., España, F., Ferrando, F., Mira, Y., and Estellés, A. (1999). Hereditary homozygous heparin cofactor II deficiency and the risk of developing venous thrombosis. Thromb. Haemost. 82, 1011–1014.

44. Bernardi, F., Legnani, C., Micheletti, F., Lunghi, B., Ferraresi, P., Palareti, G., Biagi, R., and Marchetti, G. (1996). A heparin cofactor II mutation (HCII Rimini) combined with factor V Leiden or type I protein C deficiency. Arch. Pathol. Lab. Med. 120, 136–140.

45. Vicente, C.P., He, L., and Tollefsen, D.M. (2007). Accelerated atherogenesis and neo-intima formation in heparin cofactor II deficient mice. Blood 110, 4261–4267.

46. Pai, C.W., and Zhang, G.S. (2003). [Heparin cofactor II (HCII) activity and antigen assay and their significance in thrombotic diseases]. Zhonghua Xue Ye Xue Za Zhi 24, 452–454.

47. Haringisma, H.J., Li, J.J., Soriano, F., Kenski, D.M., Flanagan, W.M., and Willingham, A.T. (2012). mRNA knockdown by single strand RNA is improved by chemical modifications. Nucleic Acids Res. 40, 4125–4136.

48. Nair, J.K., Willoughby, J.L., Chan, A., Charisse, K., Alam, M.R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel'm, A.V., Mástein, S., et al. (2014). Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 136, 16958–16961.

49. Sehgal, A., Barros, S., Ivanciu, L., Cooley, B., Qin, J., Racie, T., Hettinger, J., Carioto, M., Jiang, Y., Brodsky, J., et al. (2015). Ant RNAs therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat. Med. 21, 492–497.

50. Hatakeyama, H., Wu, S.Y., Mangala, L.S., Lopez-Berestein, G., and Sood, A.K. (2016). Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods Mol. Biol. 1402, 189–197.

51. Chen, C., Ridzon, D.A., Broomer, A.J., Zhou, Z., Lee, D.H., Nguyen, J.T., Barbisin, M., Xu, N.L., Mahuvakar, V.R., Andersen, M.R., et al. (2005). Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33, e179.

52. Vicente, C.P., He, L., Pavão, M.S., and Tollefsen, D.M. (2004). Antithrombotic activity of dermatan sulfate in heparin cofactor II-deficient mice. Blood 104, 3965–3970.

53. Gewirtz, J., Thornton, M.A., Rauova, L., and Poncz, M. (2008). Platelet-delivered factor VIII provides limited resistance to anti-factor VIII inhibitors. J. Thromb. Haemost. 6, 1160–1166.

54. Janas, M.M., Schlegel, M.K., Habris, C.E., Yilmaz, V.O., Jiang, Y., Parmar, R., Zlatav, I., Castoreno, A., Xu, H., Shulga-Morskaya, S., et al. (2018). Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity. Nat. Commun. 9, 723.